Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review.

ABSTRACT:

Background and aim

The HR-positive/HER2-negative (HR+/HER2-) advanced/metastatic breast cancer (a/mBC) treatment landscape has advanced with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), yet outcome disparities persist, particularly among older patients and black, indigenous, and people of color (BIPOC) communities. Emerging real-world evidence (RWE) since 2021 highlights the need for this updated systematic literature review.

Methods

Searches were conducted in MEDLINE^®, Embase^®, and Cochrane Databases (07/06/2019-01/09/2024) and key congress proceedings (2020-2024). Studies on CDK4/6i treatment in elderly and BIPOC patients with ≥100 participants and details on therapy line and CDK4/6i type were included. Key outcomes for synthesis were effectivene

SUBMITTER: Harbeck N 

PROVIDER: S-EPMC12394504 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature